Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Aimmune Therap

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Benzinga's Top Upgrades, Downgrades For November 20, 2017
Top Upgrades Guggenheim upgraded General Motors Company (NYSE: GM) from Neutral to Buy. General Motors shares gained 0.39 ... 
Tags HFC Benzinga APRN
From Benzinga
35 Biggest Movers From Yesterday
Gainers SenesTech Inc (NASDAQ: SNES) shares climbed 82.5 percent to close at $2.92 on Monday following an announcement that ... 
Tags SNES PETS XNET
From Benzinga
Aimmune Therapeutics Scores Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Aimmune Therapeutics shows improving technical performance. 
From Investor's Business Daily
Markets retreat ahead of Fed Chair nominee announcement
The markets retreated to close lower with the Dow falling 54 points to 23,273 as investors await the announcement of President Donald Trump's nominee for the Federal Reserve Chair. Nasdaq dropped 42... 
Tags Market News
From MarketMinute.com Market Updates
Aimmune Therapeutics soars on DBV Technologies' disappointing results
Shares of Aimmune Therapeutics Inc. (Nasdaq: AIMT) surged $7.28 to close at $32.94 after rival DBV Technologies (Nasdaq: DBVT) reported disappointing results from a Phase 3 study of the peanut allergy... 
From MarketMinute.com Stock News
Benzinga's Option Alert Recap From October 23
Benzinga Proprovides its subscribers with real-time alerts of potentially market-moving options activity. Here's a recap of ... 
Tags CWH CHKP Movers
From Benzinga
Monday's Biggest Mover: SenesTech's Stock Lifted More Than 80%
Shares of SenesTech Inc (NASDAQ: SNES) shares were up about 117 percent at one point on Monday, wresting the title of the ... 
Tags CNXR EXAC Contracts
From Benzinga
Mid-Afternoon Market Update: Exactech Surges Following Acquisition News; Eldorado Gold Shares Drop
Toward the end of trading Monday, the Dow traded up 0.08 percent to 23,348.21 while the NASDAQ declined 0.13 percent to 6,620.28. The ... 
Tags DBVT EGO KR
From Benzinga
Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today
Tags AIMT DBVT
From Motley Fool
32 Stocks Moving In Monday's Mid-Day Session
Gainers Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy ... 
Tags GE AJRD VKTX
From Benzinga
Mid-Day Market Update: Petmed Express Climbs On Earnings Beat; DBV Technologies Shares Plunge
Midway through trading Monday, the Dow traded up 0.14 percent to 23,360.45 while the NASDAQ declined 0.19 percent to 6,616.69. The ... 
Tags DBVT Benzinga Mid/Day Market Update
From Benzinga
Mid-Morning Market Update: U.S. Markets Mixed; Halliburton Beats Q3 Estimates
Following the market opening Monday, the Dow traded up 0.08 percent to 23,347.97 while the NASDAQ declined 0.25 percent to 6,612.80. The ... 
Tags CEL Mid/Morning Market Update Global
From Benzinga
25 Stocks Moving In Monday's Pre-Market Session
Gainers Aimmune Therapeutics Inc (NASDAQ: AIMT) rose 46.2 percent to $37.51 in pre-market trading in response to failed DBVT ... 
Tags CAFD DEL HAL
From Benzinga
DBV Technologies Plunges By Half On Allergy Drug Trial's Failure
Shares of DBV Technologies fell after Friday's close on reports the company's test of a drug to treat peanut allergies failed. 
From Investor's Business Daily
DBV Technologies peanut allergy drug fails key study
Oct 20 (Reuters) - Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study. 
Tags companyNews
From Reuters: Company News
Aimmune teams with Regeneron, Sanofi on peanut allergy drug
Oct 16 (Reuters) - Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug. 
Tags companyNews
From Reuters: Company News
Interesting AIMT Put And Call Options For November 17th
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT... 
Tags Stocks
From Market News Video
Sum Up The Parts: XBI Could Be Worth $106
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Notable Friday Option Activity: SPWR, CELG, AIMT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in SunPower Corp (SPWR), where a total of 13,319 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
Notable Wednesday Option Activity: VSAR, AIMT, WFT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Versartis Inc (VSAR), where a total volume of 1,652 contracts has been traded thus... 
Tags Stocks
From Market News Video
Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva
Ahead of an expected uptick in news flow next month, Credit Suisse reviewed its ratings and price targets on the shares of several ... 
Tags MYOK Analyst Ratings Jassen Pharma
From Benzinga
BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65
* Aimmune Therapeutics announces second quarter 2017 financial results 
Tags companyNews
From Reuters: Company News
Analysts Anticipate XBI Will Reach $99
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BRIEF-Aimmune enrolls first patient in Artemis European Phase 3 clinical trial
* Aimmune Therapeutics enrolls first patient in Artemis (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
How The Pieces Add Up: IBB Targets $360
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BRIEF-Aimmune to present data on peanut allergy at EAACI Congress 2017
* Aimmune Therapeutics to present data on peanut allergy in Europe at the European Academy Of Allergy and Clinical Immunology (EAACI) Congress 2017 Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy
* Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy 
Tags companyNews
From Reuters: Company News
BRIEF-CoreRx says co, Aimmune Therapeutics increased manufacturing operations in Florida
* CoreRx and Aimmune Therapeutics have increased manufacturing operations at CoreRx's ICOT Center campus in Clearwater, Florida 
Tags companyNews
From Reuters: Company News
Aimmune Therapeutics Enters Oversold Territory (AIMT)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Premarket Biotech Digest – Teva, MannKind, Quidel, Applied DNA Sciences Reported Earnings
Teva Pharmaceutical Industries announced its first quarter results. Applied DNA Sciences reported its second quarter loss at $3.4 million. 
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback